Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3999509 | Urologic Oncology: Seminars and Original Investigations | 2015 | 7 Pages |
Abstract
It may be useful to consider expression levels of potential molecular markers in the autophagy pathway, particularly ULK1, in addition to conventional parameters, when selecting patients with mRCC who are likely to benefit from treatment with mTOR inhibitors.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Masatomo M.D., Ph.D., Hideaki M.D., Ph.D., Liu M.D., Masato M.D., Ph.D.,